Baltimore Capital Management’s AbbVie ABBV Stock Holding History

Baltimore Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	$714K	Buy	+8,858	New	+$725K	1.15%	26
2018 Q3	$724K	Sell	7,658 -1,075	-12%	-$102K	1.16%	31
2018 Q2	$809K	Sell	8,733 -175	-2%	-$17.1K	1.2%	31
2018 Q1	$843K	Sell	8,908 -200	-2%	-$22K	1.26%	31
2017 Q4	$881K	Sell	9,108 -350	-4%	-$33K	1.24%	30
2017 Q3	$840K	Sell	9,458 -475	-5%	-$36.2K	1.18%	30
2017 Q2	$720K	Sell	9,933 -1,117	-10%	-$75.1K	1.04%	35
2017 Q1	$720K	Buy	+11,050	New	+$695K	0.96%	33

Other funds holding ABBV

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Baltimore Capital Management's ABBV Position: Q1 2019 in Review

Baltimore Capital Management opened a new position in AbbVie (ABBV) in Q1 2019: 8,858 shares worth $714K. The stake represents 1.15% of the portfolio and ranks #26 among its holdings. This is a return to the name: Baltimore Capital Management previously reported a position in ABBV as recently as Q3 2018.

Baltimore Capital Management first reported a position in ABBV in Q1 2017 and has held it in 8 quarters since. The position peaked at $881K in Q4 2017. 2,033 funds tracked by Wall St. Rank hold ABBV as of Q1 2019.

Baltimore Capital Management held 8,858 shares of AbbVie worth $714K as of Q1 2019.
AbbVie was a new Baltimore Capital Management position in Q1 2019.
AbbVie made up 1.15% of Baltimore Capital Management's portfolio in Q1 2019, its #26 holding.
Baltimore Capital Management first reported a position in AbbVie in Q1 2017 and has held it in 8 quarters since.
Baltimore Capital Management's AbbVie position peaked at $881K in Q4 2017.
2,033 funds tracked by Wall St. Rank held AbbVie as of Q1 2019.

Based on Baltimore Capital Management's 13F filing for Q1 2019, filed 14 May 2019.